About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in San Diego | 9,548 Studies Near You | Clareo Health

Clinical Trials LocationsSan Diego

Clinical Trials in San Diego

Discover 9,548 clinical trials near San Diego, California. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3941-3960 of 9,548 trials

COMPLETEDPhase 2< 1 mile

A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression

NCT03228394

This study will evaluate the Safety, Pharmacokinetics and Efficacy of IV Administration of Ganaxolone in Women with Postpartum Depression

DepressionDepressive DisorderDepression, Postpartum+7 more

Marinus Pharmaceuticals91 participantsStarted Jun 2017

Little Rock, Arkansas, United States • Costa Mesa, California, United States • Lemon Grove, California, United States +13 more locations

COMPLETEDPhase 3< 1 mile

Relapse Prevention Study in Patients With Schizophrenia

NCT01291511

The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia

Vanda Pharmaceuticals635 participantsStarted Feb 2011

Anaheim, California, United States • Bellflower, California, United States • Costa Mesa, California, United States +60 more locations

Find Trials by Condition in San Diego

Breast Cancerin San Diego Lung Cancerin San Diego Prostate Cancerin San Diego Colorectal Cancerin San Diego Melanomain San Diego Leukemiain San Diego Lymphomain San Diego Pancreatic Cancerin San Diego Ovarian Cancerin San Diego Brain Cancerin San Diego

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3< 1 mile

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728

This study (contRAst 3 \[202018: NCT04134728\]) is a Phase 3, randomized, multicenter, double-blind study to assess the safety and efficacy of GSK3196165 in combination with conventional (cs) DMARD\[s\]) or the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to biologic (b) DMARD\[s\]) and/or JAK inhibitors. The study will consist of a screening phase of up to 6 weeks followed by 24 week treatment phase in which participants will be randomized in ratio of 6:6:6:1:1:1 to GSK3196165 150 milligrams (mg) subcutaneously (SC) weekly,GSK3196165 90 mg SC weekly, sarilumab 200 mg SC every other week or placebo (three arms) respectively, all in combination with background csDMARD(s). At Week 12, participants in the three placebo arms will switch from placebo to active intervention (either GSK3196165 150 mg SC weekly, GSK3196165 90 mg SC weekly, or sarilumab 200 mg SC every other week). Participants who, in investigator's judgement will benefit from extended treatment with GSK3196165, may be included in the long-term extension study (contRAst X \[209564: NCT04333147\]). Any participant who does not transition into study 209564 will undergo a safety follow-up visit at Week 34 (corresponding to 12 weeks after the last potential dose of sarilumab, at Week 22).

Arthritis, Rheumatoid

GlaxoSmithKline550 participantsStarted Oct 2019

Mesa, Arizona, United States • Phoenix, Arizona, United States • Sun City, Arizona, United States +128 more locations

COMPLETEDPhase 3< 1 mile

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

NCT03354273

This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.

Coronary Artery Disease (CAD)

GE Healthcare730 participantsStarted Jun 2018

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +50 more locations

COMPLETEDPhase 38.8 miles

Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)

NCT04187144

The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

Urinary Tract Infections

GlaxoSmithKline1,606 participantsStarted Apr 2020

Birmingham, Alabama, United States • Homewood, Alabama, United States • Huntsville, Alabama, United States +110 more locations

UNKNOWNNA11 miles

PDGeneration: Mapping the Future of Parkinson's Disease

NCT04057794

To assess the feasibility, impact, and participant satisfaction of offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care for People with Parkinson's disease (PWP).

Parkinson's Disease and Parkinsonism

Parkinson's Foundation1,982 participantsStarted Aug 2019

Phoenix, Arizona, United States • La Jolla, California, United States • Fort Lauderdale, Florida, United States +10 more locations

COMPLETEDPhase 230 miles

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

NCT03679767

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.

Metastatic Non-small Cell Lung CancerLocally Advanced Urothelial CancerMetastatic Urothelial Cancer+4 more

Incyte Corporation121 participantsStarted Jan 2019

Fresno, California, United States • Fresno, California, United States • San Marcos, California, United States +49 more locations

COMPLETEDPhase 332 miles

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.

NCT03770403

This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG. Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to receive efgartigimod by SC administration.

Generalized Myasthenia Gravis

argenx151 participantsStarted Mar 2019

Carlsbad, California, United States • Los Angeles, California, United States • Orange, California, United States +49 more locations

COMPLETEDNA83 miles

Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions

NCT01092416

This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects. Study is going to enroll up to 429 subjects in up to 50 U.S. study sites. The primary safety endpoint is 30-day MACE and primary efficacy endpoint is procedural success. All subjects will be treated with the orbital atherectomy system and adjunctive stent. All subjects will be followed in clinic at 30 days. Additionally, all subjects will have an annual phone call or clinical follow up at each anniversary until study is closed.

Coronary Artery Disease

Abbott Medical Devices443 participantsStarted May 2010

Birmingham, Alabama, United States • Montgomery, Alabama, United States • Gilbert, Arizona, United States +48 more locations

TERMINATEDPhase 1/284 miles

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

NCT03970616

This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor activity of tivozanib in combination with durvalumab in subjects with advanced HCC.

Hepatocellular Carcinoma

AVEO Pharmaceuticals, Inc.27 participantsStarted Sep 2019

Gilbert, Arizona, United States • Duarte, California, United States • Orange, California, United States +7 more locations

RECRUITINGPhase 392 miles

Simple Bone Cysts in Kids

NCT02193841

Simple bone cysts (SBCs) are cysts filled with fluid that occur most frequently in the long bones (arms or legs) of children. There are many ways to treat SBCs but it is unclear if one is better than another. The purpose of this research trial is to compare the effectiveness of two common treatments that are used by surgeons today.

The Hospital for Sick Children160 participantsStarted Mar 2015

Birmingham, Alabama, United States • Loma Linda, California, United States • Wilmington, Delaware, United States +22 more locations

COMPLETEDPhase 197 miles

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05517525

The primary purpose of the study is to compare the PK of a single dose of brensocatib in participants with hepatic impairment to that in matched healthy control participants with normal hepatic function.

Hepatic Impairment

Insmed Incorporated30 participantsStarted Oct 2022

Rialto, California, United States • Orlando, Florida, United States • San Antonio, Texas, United States

COMPLETEDPhase 2109 miles

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

NCT04126733

The purpose of this study is to learn if combination of the two drugs regorafenib and nivolumab is an effective treatment for pMMR - MSS colorectal cancer, a special type of cancer of the colon or rectum (pMMR stands for proficient Mismatch Repair; MSS stands for Microsatellite Stable) and whether it is safe for patients. Regorafenib works by blocking several different proteins involved in tumor growth. Nivolumab is an immunotherapy drug encouraging the body's own immune system to attack cancer cells. Both drugs have been approved, but not for how they are being used as combination therapy in this study. Brand name of regorafenib is Stivarga; brand name of nivolumab is Opdivo.

Colorectal Cancer

Bayer70 participantsStarted Oct 2019

Duarte, California, United States • Denver, Colorado, United States • Miami, Florida, United States +12 more locations

COMPLETEDPhase 1/2111 miles

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

NCT02575963

The study is a multicenter, open label Phase I/II trial. 1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion) 2. Determine the response rate (CR + CRp + CRi) to fractionated doses of Lintuzumab-Ac225 alone (Phase 2 portion)

Actinium Pharmaceuticals40 participantsStarted Oct 2012

Los Angeles, California, United States • Lexington, Kentucky, United States • Louisville, Kentucky, United States +14 more locations

COMPLETEDNA111 miles

Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease

NCT01839396

The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced, levodopa-responsive bilateral Parkinson's disease (PD) which is not adequately controlled with medication.

Parkinson's Disease

Boston Scientific Corporation313 participantsStarted May 2013

Phoenix, Arizona, United States • Los Angeles, California, United States • Sacramento, California, United States +19 more locations

COMPLETEDPhase 1118 miles

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

NCT04747197

Phase 1 open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of a single dose injections of EYP-1901 at three dose levels: 440 µg, 2060 µg and 3090 µg in subjects with Wet Age Related Macular Degeneration (wAMD)

Wet Age-related Macular Degeneration

EyePoint Pharmaceuticals, Inc.17 participantsStarted Jan 2021

Phoenix, Arizona, United States • Beverly Hills, California, United States • Mountain View, California, United States +8 more locations

COMPLETED299 miles

Safety and Performance of Journey II XR Total Knee System

NCT03798847

The objective of this study is to estimate the safety and performance of Journey II XR TKS based on retrospective data.

Journey II XR Total Knee System

Smith & Nephew, Inc.683 participantsStarted Nov 2018

Phoenix, Arizona, United States • Aurora, Illinois, United States • Port Huron, Michigan, United States +9 more locations

COMPLETEDNA477 miles

Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis

NCT04769596

A randomized, sham-controlled, double-blind study of the NEUROMARKTM system as a treatment for chronic rhinitis

Chronic Rhinitis

Neurent Medical143 participantsStarted Feb 2021

Birmingham, Alabama, United States • Roseville, California, United States • Colorado Springs, Colorado, United States +5 more locations

COMPLETEDPhase 3628 miles

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

NCT01844518

The purpose of this study is to estimate Abatacept steady-state trough concentration (Cmin) at Day 113 in children and adolescents with pJIA

Active Polyarticular Juvenile Idiopathic Arthritis

Bristol-Myers Squibb219 participantsStarted Aug 2013

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Hartford, Connecticut, United States +54 more locations

TERMINATEDPhase 1/2932 miles

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

NCT02651675

This first-in-human study is intended to evaluate the safety and preliminary effectiveness of AAV (Adeno-associated virus)-based liver-directed gene therapy in the treatment of adults with Homozygous Familial Hypercholesterolemia (HoFH).

Homozygous Familial Hypercholesterolemia (HoFH)

REGENXBIO Inc.9 participantsStarted Mar 2016

Boca Raton, Florida, United States • Kansas City, Kansas, United States • Portland, Oregon, United States +6 more locations

PreviousPage 198 of 478Next

Diabetes

in San Diego

Heart Diseasein San Diego